Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Neutral rating on HUTCHMED (China) (NASDAQ:HCM) and raises the price target from $17 to $19.
August 01, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Paul Choi maintains a Neutral rating on HUTCHMED (China) and raises the price target from $17 to $19.
The raised price target from $17 to $19 by Goldman Sachs indicates a positive outlook on HUTCHMED (China), which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100